Danaher Q1 2026: Bioprocessing Orders Surge 30%

Danaher Corporation reported first quarter 2026 results on 21 April, with revenue up 3.5% year-on-year to $6.0 billion and adjusted diluted earnings per share growing 9.5% to $2.06. The standout in the print was bioprocessing equipment orders, which rose more than 30% year-on-year, the first positive growth in almost two years. The company raised the upper end of its full-year adjusted EPS guidance to an $8.35 to $8.55 range.

Non-GAAP core revenue grew 0.5% in the quarter, with a 2.5 percentage point headwind from a lighter-than-typical respiratory season at Cepheid offsetting 3% growth across the rest of the business. Biotechnology core revenue was up 7%, with management flagging double-digit growth in bioprocessing in China and strong consumables demand globally. Net earnings reached $1.0 billion, or $1.45 per diluted share on a GAAP basis. Operating cash flow was $1.3 billion and free cash flow $1.1 billion.

President and CEO Rainer Blair pointed to strength in bioprocessing and better-than-expected Life Sciences performance as the drivers of the quarter, partially offset by the soft Cepheid respiratory comparison. The company expects full-year 2026 non-GAAP core revenue growth of 3% to 6%, more than $5 billion in free cash flow and a second-quarter adjusted operating profit margin of approximately 26.5%. Sitting on top of the quarter is the pending $9.9 billion acquisition of Masimo Corporation, the pulse oximetry and patient monitoring specialist, which Masimo shareholders approved on 4 May 2026.

The bioprocessing order rebound is the most important commercial signal in the quarter, suggesting the long-running destocking cycle across biologics manufacturing customers is closing out. Combined with the Masimo deal, Danaher’s Q1 print sketches out a portfolio leaning further into acute care monitoring and biologics tooling, two of the more defensible growth pockets in life sciences and diagnostics over the next 12 to 18 months.